Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders
Lymphoproliferative disorders (LPDs) are serious complications associated with rheumatoid arthritis (RA) treatment that mostly occur during methotrexate (MTX) treatment. Cessation of MTX may induce regression of LPDs but is often followed by a flare of RA. Here, we describe two patients with RA flar...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2023/5780733 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568835093299200 |
|---|---|
| author | Yoshifumi Tada Akira Maeyama Tomonobu Hagio Mariko Sakai Akihito Maruyama Takuaki Yamamoto |
| author_facet | Yoshifumi Tada Akira Maeyama Tomonobu Hagio Mariko Sakai Akihito Maruyama Takuaki Yamamoto |
| author_sort | Yoshifumi Tada |
| collection | DOAJ |
| description | Lymphoproliferative disorders (LPDs) are serious complications associated with rheumatoid arthritis (RA) treatment that mostly occur during methotrexate (MTX) treatment. Cessation of MTX may induce regression of LPDs but is often followed by a flare of RA. Here, we describe two patients with RA flares after the discontinuation of MTX due to LPDs and sarilumab was useful for the treatment of RA without a relapse of LPDs. Patient 1 was an 84-year-old woman, who developed an LPD in the pharyngeal region after 7 years of MTX treatment. Discontinuation of MTX induced regression of LPD but RA flared within 6 months. Administration of sarilumab, in addition to salazosulfapyridine and prednisolone, reduced the RA activity without LPD relapse. Patient 2 was a 76-year-old man, who developed LPD in the pharyngeal region after 5 years of MTX treatment. Discontinuation of MTX induced regression of LPD, but soon RA flared. Although treatment with tocilizumab (TCZ) was effective in controlling RA, it flared again after 2 years. TCZ was switched to sarilumab and RA was in remission. LPD did not recur during these periods. |
| format | Article |
| id | doaj-art-3b152a295e404c9a9ca5528dabe611cd |
| institution | Kabale University |
| issn | 2090-6897 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-3b152a295e404c9a9ca5528dabe611cd2025-02-03T00:12:11ZengWileyCase Reports in Rheumatology2090-68972023-01-01202310.1155/2023/5780733Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative DisordersYoshifumi Tada0Akira Maeyama1Tomonobu Hagio2Mariko Sakai3Akihito Maruyama4Takuaki Yamamoto5Department of RheumatologyDepartment of Orthopaedic SurgeryDepartment of Orthopaedic SurgeryDepartment of RheumatologyDepartment of RheumatologyDepartment of Orthopaedic SurgeryLymphoproliferative disorders (LPDs) are serious complications associated with rheumatoid arthritis (RA) treatment that mostly occur during methotrexate (MTX) treatment. Cessation of MTX may induce regression of LPDs but is often followed by a flare of RA. Here, we describe two patients with RA flares after the discontinuation of MTX due to LPDs and sarilumab was useful for the treatment of RA without a relapse of LPDs. Patient 1 was an 84-year-old woman, who developed an LPD in the pharyngeal region after 7 years of MTX treatment. Discontinuation of MTX induced regression of LPD but RA flared within 6 months. Administration of sarilumab, in addition to salazosulfapyridine and prednisolone, reduced the RA activity without LPD relapse. Patient 2 was a 76-year-old man, who developed LPD in the pharyngeal region after 5 years of MTX treatment. Discontinuation of MTX induced regression of LPD, but soon RA flared. Although treatment with tocilizumab (TCZ) was effective in controlling RA, it flared again after 2 years. TCZ was switched to sarilumab and RA was in remission. LPD did not recur during these periods.http://dx.doi.org/10.1155/2023/5780733 |
| spellingShingle | Yoshifumi Tada Akira Maeyama Tomonobu Hagio Mariko Sakai Akihito Maruyama Takuaki Yamamoto Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders Case Reports in Rheumatology |
| title | Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders |
| title_full | Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders |
| title_fullStr | Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders |
| title_full_unstemmed | Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders |
| title_short | Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders |
| title_sort | usefulness of sarilumab in patients with rheumatoid arthritis after regression of lymphoproliferative disorders |
| url | http://dx.doi.org/10.1155/2023/5780733 |
| work_keys_str_mv | AT yoshifumitada usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders AT akiramaeyama usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders AT tomonobuhagio usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders AT marikosakai usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders AT akihitomaruyama usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders AT takuakiyamamoto usefulnessofsarilumabinpatientswithrheumatoidarthritisafterregressionoflymphoproliferativedisorders |